SAN FRANCISCO--(BUSINESS WIRE)--Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective ...
Primary Sclerosing Cholangitis (PSC) is a debilitating rare disease of the liver with no effective treatment. Researchers have now identified four regions of the genome associated with the disease, ...
DENVER & TORONTO — PSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the ...
Table 1 Association summary statistics across four newly associated PSC risk loci In summary, we performed the largest genome-wide association study of PSC to date and identified four new PSC risk ...
TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic ...
Primary Sclerosing Cholangitis is an orphan disease with no FDA approved therapeutic options or viable alternatives except surgical interventions. PSC is caused by dysregulation of bile homeostasis ...
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results